Build a Heart. Save a life.
BIOLIFE4D is committed to perfecting the technology to make viable organ replacement a safe, accessible and affordable reality. With BIOLIFE4D, a patient-specific, fully functioning heart will be created through 3D bioprinting and the patient’s own cells, eliminating the challenges of organ rejection and long donor waiting lists that plague existing organ transplant methods.


Investor Update!!

BIOLIFE4D is very excited to announce that we have already achieved incredible progress in our labs, we are more than a year ahead of initial time projections after only 4 months, AND we have also surpassed $1 million dollars of stock sold in our equity crowdfunding event. As a result of these incredible achievements we can also report that as of June 22nd, 2018 the share price of our stock has already reached $12 per share - a 20% increase in only 4 months. We appreciate the incredible support from all our dedicated investors.Bioprinter layering bio-ink of human heart cells  

Bioprinter layering bio-ink of human heart cells
What if we could print a human heart? Science has found a way. This is not science fiction. This is science fact. This is BIOLIFE4D.

Learn More See Bioprinting in Action

Heart cell for 3D bioprinting
It starts with a patient’s own cells and ends with a bioprinted heart that’s both a precise fit and perfect genetic match.

Learn More

Heart cell for 3D bioprinting
BIOLIFE4D is now open for investors to purchase stock and participate in the development of this remarkable new process.
Invest Now Learn More Bioprinter layering bio-ink of human heart cells

BIOLIFE4D in the News!

By Emilia Benton, Correspondent  Updated 10:11 am CDT, Tuesday, October 23, 2018 According to U.S. Government Information on Organ Donation and Transplantation, hundreds of thousands of patients across the U.S. are currently on a waiting list for a transplanted organ, and 20 people die each day waiting for a transplant. However, researchers within the Texas Medical Center…

Latest Press Releases

Pioneering biotech company reaches significant milestone well ahead of 6-8 month development time, successfully 3D bioprinting a human cardiac patch, as it seeks to produce full human hearts viable for transplant CHICAGO – June 25, 2018 – BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today…

Recent Blogs

Today is an exciting day for BIOLIFE4D. After just a few months and more than $1M in investments raised, we’re pleased to announce that we’ve modified our Regulation A+ (Mini-IPO) offering due to popular demand and that the stock price has now reached $12 per share – a 20% increase in just four months. Since…

Build a Heart. Save a life.

Invest Now

Bioprinter layering bio-ink of human heart cells

Scroll Up